{"prompt": "['2017N331008_06', 'CONFIDENTIAL', 'ViiV Healthcare group of companies', '208090', 'TITLE PAGE', 'Protocol Title: A Phase III, randomized, multicenter, open-label, non-inferiority study', 'evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine', 'fixed dose combination in HIV-1 infected adults who are virologically suppressed', 'Protocol Number: 208090 Amendment 04', 'Compound Number: GSK1349572+GR 109714 (GSK3515864)', 'Short Title: A Phase III, randomized, multicenter, open-label, non-inferiority study', 'evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine', 'fixed dose combination in HIV-1 infected adults who are virologically suppressed', 'PPD', 'Authors:', 'Sponsor Name and Legal Registered Address (excluding US):', 'ViiV Healthcare UK Limited', '980 Great West Road', 'Brentford', 'Middlesex, TW8 9GS', 'UK', 'US IND Sponsor Name and Legal Registered Address:', 'ViiV Healthcare Company', 'Five Moore Drive', 'P.O. 13398', 'Research Triangle Park, NC 27709-3398, USA', 'Telephone: PPD', 'Approval Date: 05-MAY-2020', 'Copyright 2020 ViiV Healthcare group of companies. All rights reserved. Unauthorised', 'copying or use of this information is prohibited.', '1']['2017N331008_06', 'CONFIDENTIAL', 'ViiV Healthcare group of companies', '208090', 'In some countries, local law requires that the Clinical Trial sponsor is a local', 'company legal entity. In these instances, the appropriate company to be identified', 'as Sponsor must be agreed with the global ViiV Healthcare clinical team and signed', 'off by the Vice President, Global Research and Medical Strategy', 'This study is sponsored by ViiV Healthcare. GlaxoSmithKline and PPD are supporting', 'ViiV Healthcare in the conduct of this study.', 'Medical Monitor Name and Contact Information can be found in the Study', 'Reference Manual', 'Regulatory Agency Identifying Number(s): US IND: 127475/EudraCT : 2018-000177-', '72', '2']['PPD', 'From:', 'PPD', 'Sent:', 'Wednesday, May 6, 2020 12:22 AM', 'To:', 'PPD', 'Subject:', 'FW: rot-Amend4-208090-sponsign', 'Hello,', 'Please find sponsor approval below for 208090 amendment 04.', 'Kind regards,', 'PPD', 'From: Sherene Min', 'PPD', 'Sent: Tuesday, May 05, 2020 1:38 PM', 'To: PPD', 'Subject: RE: Prot-Amend4-208090-sponsign', 'Dear', 'PPD', ',', 'I approve the protocol amendment.', 'Kind regards,', 'Sherene', 'Sherene Shakib Min, MD, MPH', 'VP, Head of Clinical Development', 'ViiV Healthcare', 'Five Moore Drive', 'RTP, NC. 27709', 'PPD', 'M: PPD', 'PPD', '1']\n\n###\n\n", "completion": "END"}